ArticleGut2000
Expression of CD44 variants and prognosis in oesophageal squamous cell carcinoma.
Article in Gut, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Meta-Analysis of Prognostic and Clinical Significance of CD44v6 in Esophageal Cancer.Medicine · 2015Pooled it
- Homeobox A10 in gastrointestinal malignancies: unraveling metastatic mechanisms and novel therapeutic opportunities.Cancer metastasis reviews · 2026Review
- A non-toxic, reversibly released imaging probe for oral cancer that is derived from natural compounds.Scientific reports · 2021Article
- Role of MAML1 in targeted therapy against the esophageal cancer stem cells.Journal of translational medicine · 2019Article
- An adhesion based approach for the detection of esophageal cancer.Integrative biology : quantitative biosciences from nano to macro · 2018Article
- Article
- Gli1, a potential regulator of esophageal cancer stem cell, is identified as an independent adverse prognostic factor in esophageal squamous cell carcinoma.Journal of cancer research and clinical oncology · 2017Article
- Hyaluronic acid in digestive cancers.Journal of cancer research and clinical oncology · 2017Review
- The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer.Stem cells international · 2016Review
- Cancer stem cell detection and isolation.Medical oncology (Northwood, London, England) · 2014Review
- Increased CD44s and decreased CD44v6 RNA expression are associated with better survival in myxofibrosarcoma patients: a pilot study.European journal of medical research · 2014Article
- Expression of CD44v6 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma.Oncology letters · 2011Article
- CD44 upregulation in E-cadherin-negative esophageal cancers results in cell invasion.PloS one · 2011Article
- Tumor initiating cells in esophageal squamous cell carcinomas express high levels of CD44.PloS one · 2011Article
- Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus.World journal of gastroenterology · 2006Article
- Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value.Journal of clinical pathology · 2005Review
- CD44v6: a target for antibody-based cancer therapy.Cancer immunology, immunotherapy : CII · 2004Review
- Significance of immunohistochemical over-expression of CD44v6 as an indicator of malignant potential in esophageal squamous cell carcinoma.Journal of cancer research and clinical oncology · 2004Article
- Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma.Annals of surgery · 2003Article
- Clinicopathological significance of expression of CD44 variants in head and neck squamous cell carcinoma.Japanese journal of cancer research : Gann · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe CD44 variant (CD44v) isoforms have been noted as markers for tumour metastasis and prognosis in several adenocarcinomas.
aimsTo investigate whether CD44v, especially the CD44v2 (v2) isoform, may be a useful prognostic factor for patients with oesophageal squamous cell carcinoma, using a recently developed monoclonal antibody against a v2 epitope. PATIENTS: 233 patients (211 men and 22 women; mean age 61.9 years), with oesophageal squamous cell carcinomas curatively removed without additional treatment between 1987 and 1996 at the National Cancer Center Hospital, were analysed for CD44v expression.
methodsThe expression of CD44v was evaluated immunohistochemically using monoclonal antibodies against epitopes of the standard and variant protein, in paraffin embedded oesophageal squamous cell carcinoma tissue from 233 patients who had undergone cervical, mediastinal, and abdominal lymphadenectomy (three field dissection) for oesophagectomy. The data were evaluated for any correlation with clinicopathological indices or prognosis.
resultsAlthough total CD44 and CD44v6 (v6) were respectively observed in 99% and 97% of the cancer specimens, the expression of v2 was only 30%. Patients whose tumours were v2 positive had a significantly better prognosis than those whose tumours were v2 negative (p = 0.031). Furthermore, in patients without lymph node metastasis, v2 positivity alone was a significant independent factor of prognosis (relative risk of death associated with v2 negativity, 4.7; p = 0.037) in multivariate analysis.
conclusionsThese results indicate that v2 is a useful marker for clinical prognosis in patients with oesophageal squamous cell carcinoma. Particularly in patients without lymph node metastasis, v2 status may thus have implications for the use of adjuvant chemotherapy and/or radiotherapy in patients with oesophageal cancer at an early stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.